Biopharmaceutical benchmarks 2014
G Walsh - Nature biotechnology, 2014 - nature.com
Nature biotechnology, 2014•nature.com
Biopharmaceutical benchmarks 2014 | Nature Biotechnology Skip to main content Thank you
for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are
displaying the site without styles and JavaScript. Advertisement Nature Biotechnology View all
journals Search My Account Explore content About the journal Publish with us Sign up for …
for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are
displaying the site without styles and JavaScript. Advertisement Nature Biotechnology View all
journals Search My Account Explore content About the journal Publish with us Sign up for …
Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.
nature.com
